Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicyclol in Acute Drug-induced Liver Injury
NCT05063500Phase 3Unknown
- Sponsor
- Spanish Drug-Induced Liver Disease Study Group
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bicyclol in acute drug-induced liver injury (DILI) (2 arms), sponsored by Spanish Drug-Induced Liver Disease Study Group. Primary endpoint: The normalization rate of serum ALT after 4 weeks of treatment. Status: unknown.
02
Drugs
bicyclol
03
Conditions
acute drug-induced liver injury (DILI)
Beyond the preview
Go deeper on NCT05063500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063500.